Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P. Patient and caregiver burden associated with fragile x syndrome in the United States. Am J Intellect Dev Disabil. 2015 Sep;120(5):444-59. doi: 10.1352/1944-7558-120.5.444
Kovac AL, Pearman MH, Khalil SN, Scuderi PE, Joslyn AF, Prillaman BA, Cox F. Ondansetron prevents postoperative emesis in male outpatients.S3A-379 study group. J Clin Anesth. 1996 Dec;8(8):644-51. doi: 10.1016/s0952-8180(96)00173-0